Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review)

Chemotherapy
M Kissling, N Bergamini

Abstract

A review of the published literature has allowed the identification of a number of non-tubercular indications where rifampicin (trade mark Ciba-Geigy: Rimactane) has been successfully used in combination with other chemotherapeutic agents. The cases reviewed with regard to effectiveness sum 562. The most frequently combined drugs were aminoglycosides (mainly gentamicin), cotrimoxazole, colistine, vancomycin and fusidic acid, these two latter in cases due to Staphylococcus spp. The main indications where combined rifampicin treatment led to favourable results were UTI (success rate 64.9%), bone infections (86.9%), staphylococcal endocarditis (85.0%), respiratory tract infections often due to gram-negative rods (97.7%) as well as skin and soft tissue infections (83.3%), and bacterial meningitis (100%). Very favourable results were obtained in a non-life-threatening though epidemiologically important condition, i.e. salmonella carriers, where a 100% conversion rate was reached in an average period of 6 weeks. Special attention may deserve the combined treatment of fungal infections with rifampicin and amphotericin B. Tolerability was evaluated on a total of 650 cases. It appears to be good for daily doses up to 1,200 mg/day, even ...Continue Reading

Citations

Jan 1, 1981·The Journal of International Medical Research·M Kissling, M Xilinas
Jul 1, 1985·Infection·C Simon, G Littschwager
Oct 1, 1986·Drug Intelligence & Clinical Pharmacy·M D Katz, E Lor
Aug 25, 1984·British Medical Journal·W Brumfitt, J M Hamilton-Miller
Apr 1, 1984·Annals of Tropical Medicine and Parasitology·J El-OnC L Greenblatt
Aug 25, 1984·British Medical Journal·T Benson
Feb 1, 1985·European Journal of Clinical Microbiology·S DixsonJ M Hamilton-Miller
Aug 23, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I A BliziotisM E Falagas
Nov 27, 2018·Expert Review of Clinical Pharmacology·Fiona V CresswellReinout Van Crevel
Feb 6, 2015·American Journal of Respiratory and Critical Care Medicine·Martin J BoereeUNKNOWN PanACEA Consortium
Jan 23, 2020·Journal of Materials Science. Materials in Medicine·Aysenur TopsakalOguzhan Gunduz
Oct 6, 2007·The Journal of Antibiotics·Christopher K MurphyDavid M Rothstein
Dec 17, 2008·Antimicrobial Agents and Chemotherapy·Jossy van den BoogaardRob E Aarnoutse
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Christopher K MurphyDavid M Rothstein
Jul 1, 1994·Antimicrobial Agents and Chemotherapy·S G FranzblauT P Gillis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.